Sandoz Launches Semaglutide In Brazil

By Reuters News

- SANDOZ GROUP AG SDZ.S:

  • SANDOZ LAUNCHES NEW SEMAGLUTIDE TREATMENT OPTION IN BRAZIL, EXPANDING PATIENT ACCESS TO GLP-1 MEDICINE IN KEY GLOBAL MARKET

  • NO MATERIAL FINANCIAL CONTRIBUTION EXPECTED FROM SANDOZ SEMAGLUTIDE LAUNCH THIS YEAR

  • OWOZY APPROVED IN 1.5 ML AND 3.0 ML PRE-FILLED PEN PRESENTATIONS

  • BIOLAB & CO TO COMMERCIALISE OWOZY IN BRAZIL

  • BRAZIL GLP-1 MARKET VALUED AT ESTIMATED $2.70 BILLION

Further company coverage: SDZ.S

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk